2002
DOI: 10.1001/archderm.138.1.42
|View full text |Cite
|
Sign up to set email alerts
|

Quantifying Skin Disease Burden in Mycosis Fungoides–Type Cutaneous T-Cell Lymphomas

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

2
62
0
2

Year Published

2002
2002
2017
2017

Publication Types

Select...
9

Relationship

3
6

Authors

Journals

citations
Cited by 88 publications
(66 citation statements)
references
References 26 publications
2
62
0
2
Order By: Relevance
“…Intervening outcomes at 5 months of ECP were defined as follows: complete remission, no evidence of disease on results of physical examination, computed tomographic scans, blood examination for circulating Sézary cells, or abnormal immunophenotype by means of flow cytometry; partial remission, greater than 50% reduction in the skin severity score. 13 Responders are those who achieved a partial or a complete remission, whereas stable disease indicated less than a 50% reduction in the skin severity score. Data were analyzed by 2 and 2-tailed Fisher exact test.…”
Section: Methodsmentioning
confidence: 99%
“…Intervening outcomes at 5 months of ECP were defined as follows: complete remission, no evidence of disease on results of physical examination, computed tomographic scans, blood examination for circulating Sézary cells, or abnormal immunophenotype by means of flow cytometry; partial remission, greater than 50% reduction in the skin severity score. 13 Responders are those who achieved a partial or a complete remission, whereas stable disease indicated less than a 50% reduction in the skin severity score. Data were analyzed by 2 and 2-tailed Fisher exact test.…”
Section: Methodsmentioning
confidence: 99%
“…The most widely used method for skin scoring is the Severity Weighted Assessment Tool (SWAT) 8,9 or its modification, the mSWAT. 10 This technique involves the direct assessment of the body-surface area (BSA) of each type of MF/SS lesion (palm plus fingers of the patient ϭ approximately 1% BSA) in each of 12 areas of the body, multiplying the sum of the BSA of each lesion type by a weighting factor (patch ϭ 1, plaque ϭ 2, and tumor ϭ 3 or 4) and generating a sum of the subtotals of each lesion subtype (Table 3 There has been much discussion about the appropriate weighting factor for tumors given their prognostic importance.…”
Section: Skin Assessment and Scoringmentioning
confidence: 99%
“…The modified Severity Weighted Assessment Tool was used for quantitative assessment of disease burden in the skin of all patients. 20,21 Positron emission tomography/computed tomography scans were used to determine activity of mogamulizumab treatment in lymph nodes and viscera of all patients. Finally, MFC was used to monitor the number of circulating CTCL/Sézary cells in peripheral blood based on aberrancies in expression levels of CD3, CD4, CD7, and/or CD26.…”
Section: Disease Assessment and Response Criteriamentioning
confidence: 99%